Ratko Delić1, Mario Štefanović2, Štefka Krivec3, Vladimir Weber4, Jakob Koren4. 1. Department of Gynecology & Obstetrics, General Hospital Celje, Oblakova 5, 3000, Celje, Slovenia. rdelic@gmail.com. 2. Clinical Institute of Chemistry, Sestre Milosrdnice University Hospital, Zagreb, Croatia. 3. Department of Laboratory Medicine, General Hospital, Celje, Slovenia. 4. Department of Gynecology & Obstetrics, General Hospital Celje, Oblakova 5, 3000, Celje, Slovenia.
Abstract
OBJECTIVE: The aim of this study was to measure serum concentrations of human epididymis protein 4 (HE4) in premenopausal and postmenopausal women with benign adnexal tumors and compare HE4 levels with those of cancer antigen 125 (CA125) measured in the same samples. METHODS: In a retrospectively designed, monocentric study (Department of Gynecology & Obstetrics, General Hospital, Celje, Slovenia, EU), 147 women diagnosed with various benign adnexal tumors were included. Preoperative HE4 and CA125 levels were obtained and analyzed with regard to histopathological classification, menopausal status, and age distribution. RESULTS: A marked difference was observed in patients with endometriomas in which mean CA125 was elevated above the reference range in the premenopausal (mean 90.1 U/ml) and postmenopausal groups (mean 48.5 U/ml), while HE4 levels were within the reference range, irrespective of age or menopausal status. Inflammatory adnexal tumors were associated with elevated levels of CA125 (mean 142.2 U/ml, premenopausal and mean 62.4 U/ml, postmenopausal patients); HE4 levels were not elevated regardless of age or menopausal status. CONCLUSION: HE4 is elevated less frequently than CA125 in benign adnexal tumors, regardless of age or menopausal status.
OBJECTIVE: The aim of this study was to measure serum concentrations of humanepididymis protein 4 (HE4) in premenopausal and postmenopausal women with benign adnexal tumors and compare HE4 levels with those of cancer antigen 125 (CA125) measured in the same samples. METHODS: In a retrospectively designed, monocentric study (Department of Gynecology & Obstetrics, General Hospital, Celje, Slovenia, EU), 147 women diagnosed with various benign adnexal tumors were included. Preoperative HE4 and CA125 levels were obtained and analyzed with regard to histopathological classification, menopausal status, and age distribution. RESULTS: A marked difference was observed in patients with endometriomas in which mean CA125 was elevated above the reference range in the premenopausal (mean 90.1 U/ml) and postmenopausal groups (mean 48.5 U/ml), while HE4 levels were within the reference range, irrespective of age or menopausal status. Inflammatory adnexal tumors were associated with elevated levels of CA125 (mean 142.2 U/ml, premenopausal and mean 62.4 U/ml, postmenopausal patients); HE4 levels were not elevated regardless of age or menopausal status. CONCLUSION:HE4 is elevated less frequently than CA125 in benign adnexal tumors, regardless of age or menopausal status.
Entities:
Keywords:
Age; Benign adnexal tumor; CA125; HE4; Menopausal status
Authors: Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian Journal: Am J Obstet Gynecol Date: 2011-12-30 Impact factor: 8.661
Authors: Mona A Karlsen; Estrid V S Høgdall; Ib J Christensen; Christer Borgfeldt; Grigorios Kalapotharakos; Lenka Zdrazilova-Dubska; Josef Chovanec; Christianne A R Lok; Anna Stiekema; Irene Mutz-Dehbalaie; Adam N Rosenthal; Elizabeth K Moore; Beth A Schodin; Walfrido W Sumpaico; Karin Sundfeldt; Björg Kristjansdottir; Ignacio Zapardiel; Claus K Høgdall Journal: Gynecol Oncol Date: 2015-06-16 Impact factor: 5.482
Authors: R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp Journal: N Engl J Med Date: 1983-10-13 Impact factor: 91.245
Authors: T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote Journal: Br J Cancer Date: 2011-02-08 Impact factor: 7.640
Authors: K Huhtinen; P Suvitie; J Hiissa; J Junnila; J Huvila; H Kujari; M Setälä; P Härkki; J Jalkanen; J Fraser; J Mäkinen; A Auranen; M Poutanen; A Perheentupa Journal: Br J Cancer Date: 2009-03-31 Impact factor: 7.640